^
Association details:
Biomarker:ALK G1202K
Cancer:Lung Adenocarcinoma
Drug:Avastin (bevacizumab) (VEGF-A inhibitor)
Direction:Resistant
Evidence:
Evidence Level:
Resistant: C4 – Case Studies
New
Title:

Identification of Novel Alectinib-Resistant ALK Mutation G1202K with Sensitization to Lorlatinib: A Case Report and in silico Structural Modelling

Published date:
03/25/2021
Excerpt:
A 50-year-old Chinese male non-smoker with lung adenocarcinoma...the patient benefited from the therapy of Alectinib with a PFS of 8 months. Then he progressed with metastases in right lung and pleural, and did not show response to the chemotherapy with Docetaxel plus Bevacizumab....The targeted sequencing consistently identified EML4-ALK gene fusion in both plasma and pleural effusion (PE), as well as a novel ALK G1202K mutation (c.3604_3605delGGinsAA).
DOI:
10.2147/OTT.S293901